.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,351,691

« Back to Dashboard

Claims for Patent: 7,351,691

Title:Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/584,908
Patent Claims: 1. A compound of formula II: ##STR00009## or a pharmaceutically-acceptable salt thereof; wherein R.sup.3, R.sup.5 and R.sup.20 are selected from: TABLE-US-00016 R.sup.3 R.sup.5 R.sup.20 (a) phosphono- H CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- methylamino (b) phosphono- H CH.sub.3(CH.sub.2).sub.9OCH.sub.2CH.sub.2-- methylamino (c) phosphono- H CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- methylamino (d) phosphono- H CH.sub.3(CH.sub.2).sub.12-- methylamino (e) phosphono- H 4-(4-chlorophenyl)benzyl methylamino (f) phosphono- H 2-(4-(4-chlorophenyl)- methylamino benzylamino)ethyl (g) phosphono- H 4-(4'-chlorobiphenyl)butyl methylamino (h) phosphono- H 5-(4'-chlorobiphenyl)pentyl methylamino (i) 3-phosphono- H CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- propylamino (j) 2-hydroxy-2- H 4-(4-chlorophenyl)benzyl phosphono- ethylamino (k) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- aminomethyl (l) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- aminomethyl (m) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.9OCH.sub.2CH.sub.2-- aminomethyl (n) OH (phosphonomethyl)- CH.sub.3(CH.sub.2).sub.12-- aminomethyl (o) OH (phosphonomethyl)- 4-(4-chlorophenyl)benzyl aminomethyl (p) OH (phosphonomethyl)- 2-(4-(4-chlorophenyl)- aminomethyl benzylamino)ethyl (q) OH (phosphonomethyl)- 4-(4'-chlorobiphenyl)butyl aminomethyl (r) OH (phosphonomethyl)- 5-(4'-chlorobiphenyl)pentyl aminomethyl (s) OH (phosphonomethyl)- 3-[4-(4-chlorobenzyloxy)- aminomethyl benzylthio]propyl (t) OH N-(2-hydroxy-2- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- phosphonoethyl)- aminomethyl (u) OH N-(carboxymethyl)- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- N-2-phosphono- methyl)aminomethyl (v) OH N,N-bis(phosphono- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.sub.2-- methyl)aminomethyl (w) OH 3-phosphonopropyl- CH.sub.3(CH.sub.2).sub.9SCH.sub.2CH.sub.2-- aminomethyl (x) OH 3-phosphonopropyl- 4-(4-chlorophenyl)benzyl aminomethyl (y) phosphono- --CH.sub.2--N--(N-- CH.sub.3(CH.sub.2).sub.9NHCH.sub.2CH.su- b.2--; methylamino CH.sub.3--D-glucamine and (z) OH (phosphonomethyl)- --(CH.sub.2).sub.3NH--SO.sub.2--4-(4- aminomethyl chlorophenyl)phenyl.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

3. A lyophilized composition comprising a compound of claim 1.

4. The composition of claim 2 or 3, wherein the composition further comprises a cyclodextrin.

5. The composition of claim 4, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.

6. The composition of claim 4, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin.

7. The composition of claim 2, wherein the composition further comprises an excipient selected from mannitol, sucrose, lactose and combinations thereof.

8. The composition of claim 2, wherein the composition further comprises mannitol.

9. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.

10. The method of claim 9, wherein the bacterial disease is a staphylococcal infection.

11. The method of claim 10, wherein the staphylococcal infection is caused by Staphylococcus aureus.

12. The method of claim 10, wherein the staphylococcal infection is caused by Staphylococcus epidermidis.

13. The method of claim 10, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.

14. The method of claim 10, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis.

15. The method of claim 9, wherein the compound is administered intravenously.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc